BG105360A - Модулиране на сложна линия киназни белтъци - Google Patents

Модулиране на сложна линия киназни белтъци Download PDF

Info

Publication number
BG105360A
BG105360A BG105360A BG10536001A BG105360A BG 105360 A BG105360 A BG 105360A BG 105360 A BG105360 A BG 105360A BG 10536001 A BG10536001 A BG 10536001A BG 105360 A BG105360 A BG 105360A
Authority
BG
Bulgaria
Prior art keywords
group
carbon atoms
protein
alkyl
carbons
Prior art date
Application number
BG105360A
Other languages
Bulgarian (bg)
English (en)
Inventor
Anna Maroney
Craig DIONNE
Ernest KNIGHT Jr.
Kevin Walton
Marcie Glicksman
Nicola Neff
Original Assignee
Cephalon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.
Publication of BG105360A publication Critical patent/BG105360A/bg

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
BG105360A 1998-08-26 2001-03-19 Модулиране на сложна линия киназни белтъци BG105360A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9798098P 1998-08-26 1998-08-26
PCT/US1999/018864 WO2000013015A1 (fr) 1998-08-26 1999-08-18 Modulation de proteines kinase a lignee multiple

Publications (1)

Publication Number Publication Date
BG105360A true BG105360A (bg) 2001-10-31

Family

ID=22266038

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105360A BG105360A (bg) 1998-08-26 2001-03-19 Модулиране на сложна линия киназни белтъци

Country Status (25)

Country Link
EP (1) EP1105728B1 (fr)
JP (1) JP2002523780A (fr)
KR (1) KR100700028B1 (fr)
CN (3) CN1206535C (fr)
AT (1) ATE293254T1 (fr)
AU (1) AU765637B2 (fr)
BG (1) BG105360A (fr)
BR (1) BR9913190A (fr)
CA (1) CA2339539A1 (fr)
CZ (1) CZ2001701A3 (fr)
DE (1) DE69924738T2 (fr)
DK (1) DK1105728T3 (fr)
EA (2) EA006648B1 (fr)
ES (1) ES2241316T3 (fr)
HK (1) HK1037722A1 (fr)
HU (1) HUP0103079A3 (fr)
NO (1) NO20010389L (fr)
NZ (1) NZ509612A (fr)
PL (1) PL346246A1 (fr)
PT (1) PT1105728E (fr)
SK (1) SK2542001A3 (fr)
TR (2) TR200400635T2 (fr)
UA (1) UA74772C2 (fr)
WO (1) WO2000013015A1 (fr)
ZA (1) ZA200100835B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
BR0113266A (pt) * 2000-08-11 2005-01-04 Cephalon Inc Métodos para modular proteìnas quinase de linhagem múltipla e compostos protetores que modulam proteìnas quinase de linhagem múltipla
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
FR2826653B1 (fr) * 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2003052395A (ja) * 2001-08-09 2003-02-25 Japan Tissue Engineering:Kk 移植適正判定方法
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
EP2240783A2 (fr) * 2008-02-04 2010-10-20 Galapagos N.V. Cibles moléculaires et composés, procédés permettant de les identifier, à utiliser dans le traitement des maladies neurodégénératives
US20100056609A1 (en) * 2008-08-26 2010-03-04 Washington University Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway
AU2015202365B2 (en) * 2008-10-22 2016-11-24 Genentech, Inc. Modulation of axon degeneration
KR20110081862A (ko) * 2008-10-22 2011-07-14 제넨테크, 인크. 축삭 변성의 조절
CN102573855A (zh) * 2009-10-22 2012-07-11 霍夫曼-拉罗奇有限公司 轴突变性的调节
ES2385157B1 (es) * 2010-02-25 2013-07-08 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
US9539259B2 (en) 2012-05-23 2017-01-10 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
CN109060472A (zh) * 2018-07-20 2018-12-21 上海市农业科学院 一种适于荧光染色的草菇菌褶组织切片的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions

Also Published As

Publication number Publication date
HUP0103079A3 (en) 2004-03-01
BR9913190A (pt) 2001-12-11
ES2241316T3 (es) 2005-10-16
UA74772C2 (en) 2006-02-15
NO20010389D0 (no) 2001-01-23
SK2542001A3 (en) 2002-06-04
EA006648B1 (ru) 2006-02-24
EP1105728B1 (fr) 2005-04-13
ZA200100835B (en) 2002-06-26
DE69924738T2 (de) 2006-03-02
NO20010389L (no) 2001-04-02
CZ2001701A3 (cs) 2002-04-17
CN1314999A (zh) 2001-09-26
CA2339539A1 (fr) 2000-03-09
KR100700028B1 (ko) 2007-03-27
PT1105728E (pt) 2005-07-29
ATE293254T1 (de) 2005-04-15
TR200100589T2 (tr) 2001-07-23
NZ509612A (en) 2003-10-31
WO2000013015A1 (fr) 2000-03-09
HUP0103079A2 (hu) 2001-12-28
KR20010103573A (ko) 2001-11-23
EP1105728A1 (fr) 2001-06-13
TR200400635T2 (tr) 2005-10-21
EA200100278A1 (ru) 2002-06-27
HK1037722A1 (en) 2002-02-15
CN1589788A (zh) 2005-03-09
AU765637B2 (en) 2003-09-25
AU5679399A (en) 2000-03-21
DE69924738D1 (de) 2005-05-19
JP2002523780A (ja) 2002-07-30
EA200500934A1 (ru) 2006-04-28
DK1105728T3 (da) 2005-08-08
CN1206535C (zh) 2005-06-15
PL346246A1 (en) 2002-01-28
WO2000013015A8 (fr) 2000-05-11
CN1879617A (zh) 2006-12-20

Similar Documents

Publication Publication Date Title
BG105360A (bg) Модулиране на сложна линия киназни белтъци
Ge et al. Glutaminolysis promotes collagen translation and stability via α-ketoglutarate–mediated mTOR activation and proline hydroxylation
JP4481493B2 (ja) 架橋インデノピロロカルバゾール
PL212956B1 (pl) Zastosowanie zwiazku o wzorze I lub II, zwiazek o wzorze II, oraz kompozycja farmaceutyczna zawierajaca zwiazek o wzorze II
KR101964954B1 (ko) 뉴로트로핀 수용체의 효현제 및 약제로서의 이의 용도
JP2010536367A5 (fr)
Ding et al. TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance
KR101321284B1 (ko) 프로게린 발현 억제제를 유효성분으로 함유하는 노화 관련 질환 치료용 약학조성물 및 상기 프로게린 발현 억제제의 스크리닝 방법
AU2001283179B2 (en) Modulating multiple lineage kinase proteins
AU2001283179A1 (en) Modulating multiple lineage kinase proteins
WO2019167973A1 (fr) Inhibiteur d'évolution de cycle cellulaire
MXPA01002020A (en) Modulating multiple lineage kinase proteins
Lal et al. Calmodulin-dependent cyclic nucleotide phosphodiesterase in human cerebral cortex and glioblastoma multiforme
CN114887064A (zh) Aars1抑制剂在制备治疗或预防癌症的药物中的用途